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Background: Rapid and accurate techniques are always welcomed for the detection of resis-
tant strains of Mycobacterium tuberculosis MTB.
Objectives: The objective of this study is to evaluate the pyrosequencing technology for the
detection of MTB resistance to Rifampicin (RIF) and Isoniazid (INH) in Syrian and Lebanese
clinical strains; 66 strains resistant to INH, among them 56 resistant also to RIF, were tested.
Methods: Four pyrosequencing assays were optimized and applied to the following loci:
rpoBrpoB RIF resistance-determining region, katG, the promoter regions of inhA and
ahpC-oxyR intergenic region.
Results: The prevalence of mutations on codon 315 of the katG gene, inhA and ahpc-oxyR
were 42.4%, 21.2% and 9.0%, respectively, which make an overall sensitivity of 72.6% for
INH resistance. All RIF-resistant strains contained at least one non-synonymous codon
change in the sequenced rpoB region (507–533) relative to the ATCC reference strain. The
RIF drug resistance region (RRDR) sequencing identified 96 modified codons representing
34 different mutations.
Conclusions: The high sensitivity and the short turnaround time combined with multilocus
sequencing of several isolates in parallel make pyrosequencing an attractive method for
drug resistance screening for MTB.
 2015 Asian African Society for Mycobacteriology. Production and hosting by Elsevier Ltd.
All rights reserved.Introduction
Currently, tuberculosis (TB) in Lebanon is highly affected by
the Syrian crisis. Before the beginning of this crisis in 2011,
the estimated prevalence of TB in Lebanon was 19 per
100,000 population. The Lebanese National TuberculosisProgramme (NTP) indicates that currently over half of the
people referred to the NTP for investigations and treatment
are non-Lebanese nationals [1]. As of August 2013, according
to the NTP, 100 Syrian refugees have been diagnosed with
TB in Lebanon, including 3 cases of multidrug-resistant TB
(MDR-TB). Furthermore, during the first half of 2014, 61 casesnon.
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senting 17% of all TB cases notified [1]. The NTP in Lebanon
follows DOTS (Directly Observed Treatment Strategy), which
has a high treatment success rate among Lebanese nationals.
However, the treatment success rate is below that desired
among the non-Lebanese patients due to their departure
during the treatment [1]. MDR-TB, which is defined as being
resistant to at least INH or RIF – the two most powerful
first-line anti-TB treatment drugs – is emerging [2].
Weakened or disrupted services for the Syrian refugees can
complicate diagnosis and treatment, potentially leading to
an increase in MDR-TB. INH-resistant strains most commonly
carry mutations on the katG gene, on the promoter region of
the inhA gene and on the ahpC-oxyR intergenic region [3].
Mutations in several other genes may also lead to INH resis-
tance, but are less common [4]. RIF-resistant strains serve
as a surrogate marker for MDR-TB detection [5]. Resistance
in RIF has been attributed to mutations within an 81-bp
RRDR of the rpoB gene, corresponding to codons 509–533 [5].
Mutations outside of RRDR have also been reported, with a
frequency of <2% [6]. Culture-based drug susceptibility testing
(DST) may take 4 weeks from specimen collection to results.
At present, pyrosequencing had become a novel approach
used for the detection of TB infection and resistance. The
objective of this study is to evaluate the pyrosequencing
technology for the detection of MTB resistance to RIF and
INH in the Syrian and Lebanese clinical strains.
Materials and methods
Bacterial strains
66 strains of MTB resistant to INH, among them 56 resistant
also to RIF, were tested. These clinical isolates were provided
by the Medical Biotechnology Section of the National
Commission for Biotechnology in Syria and the health and
environment microbiology laboratory at Azm Center for
Research in Biotechnology at the Lebanese University
between July 2003 and October 2005 [7,8]. The drug resistance
pattern of the Syrian samples was previously established
according to the recommendations of the National
Committee for Clinical Laboratory Standards [8]. Antibiotic
susceptibility testing of the Lebanese strains was performed
using a BBLTM MGITTM (Mycobacteria Growth Indicator Tube)
AST system (Becton Dickinson, Franklin Lakes, NJ), based on
comparing the growth of the MTB strains in a drug-
containing tube with that of a drug-free tube [7]. All isolates
were stored at 80 C. The reference strain H37Rv (ATCC
25177) was used as a control for the wild-type sequence.
Polymerase chain reaction
The primers used to amplify and sequence the katG gene, the
promoter region of the inhA gene and the ahpC-oxyR inter-
genic region were synthesized according to Zhao et al. [9],
and those for RRDR were synthesized according to Bravo
et al. [10] by ThermoScientific, USA (Table 1). Amplification
of the target regions was performed in a thermal cycler
(MyCycler C1000; Bio-Rad). The efficacy of the amplificationwas determined by gel electrophoresis. The polymerase chain
reaction (PCR) products obtained from this step were used for
pyrosequencing.
Pyrosequencing
Sample preparation for pyrosequencing was performed
according to the manufacturer’s instructions. Single-
stranded DNA amplicons were prepared semi-automatically
using a Vacuum Prep Tool and Vacuum Prep Worktable
(Biotage, Uppsala, Sweden). A 20 ll aliquot of biotinylated
PCR product was immobilized onto 4 ll of streptavidin-
coated SepharoseTM High Performance Beads (Amersham
Biosciences, Piscataway, NJ, USA) with 26 ll of binding buffer,
pH 7.6 (10 mM Tris–HCl, 2 M NaCl, 1 mM ethylenediaminete-
traacetic acid [EDTA], 0.1% Tween 20) and incubated at 65 C
under agitation at 1400 rpm for at least 5 min. Double-
stranded DNA immobilized on Sepharose beads was washed
with 70% ethanol and denatured with 0.2 M NaOH. Unbound
single-stranded DNA was washed with 0.1 M Wash buffer
(0.1 M Tris–HCl [pH 7.6]). The beads carrying single-stranded
DNA amplicons were suspended in 38.4 ll of annealing buffer,
pH 7.6 (20 mM Tris–acetate, 5 mM Mg-acetate) containing
200 nmol of sequencing primers (Table 1). The single-
stranded DNA was annealed to the sequencing primer at
80 C for 2 min followed by incubation for 2 min at room tem-
perature. The single-stranded PCR products were sequenced
using the PyroMarkTM Q96 ID System (Biotage). To identify
point mutations, sequences from clinical isolates were com-
pared with that of wild-type MTB ATCC 25177. An internal
control was also used to validate the results.
Ethics approval
The research was approved by the responsible institutional
ethics committee of the Lebanese University.
Results
For the INH resistance, the results (Table 2) showed that
among the 66 isolates, 28 (42.4%), 14 (21.2%), and 6 (9%) had
mutations on codon 315 of the katG gene, on the promoter
region of the inhA gene and on the ahpC-oxyR intergenic
region, respectively. The overall sensitivity for INH resistance
detection by pyrosequencing is 72.6%. The most common
katG mutation was Ser315Thr (92.8%). All inhA promoter
region mutated strains had the 15 C-T mutation. For the
ahpC-oxyR intergenic region, the most common mutation
was 46 G-A (4 of 6 strains). Four strains had mutations in
katG in addition to ahpc-oxyR mutations and 1 strain had both
katG and inhA mutations.
Of the 56 RIF-resistant clinical isolates analyzed, all
strains contained at least 1 non-synonymous codon change
in the sequenced rpoB region (507–533) relative to the ATCC
reference strain (Table 3). The pyrograms indicated the pres-
ence of 97 modified codons representing 34 different codon
changes (Table 3). One codon change was a consequence of
a single base pair deletion. Five codon changes resulted in
silent mutations through nucleotide substitutions, and the
Table 3 – Number and percentage of mutated strains on rpoB region.
Nb of strains (%) Codon and Amino acid change
ATCC 25177 No mutation
21 (37.5%) 531 TCG ! TTG (Ser) ! (Leu)
5 (8.9%) 531 TCG ! TTG (Ser) ! (Leu); 533 CTG ! CGT (Leu) ! (Arg)
3 (5.3%) 531 TCG ! TTG (Ser) ! (Leu); 533 CTG ! CGT (Leu) ! (Arg)
2 (3.5%) 526 CAC ! CGC (His) ! (Arg); 528 CGC ! ACG (Arg) ! (Thr); 533 CTG ! CCG (Leu) ! (Pro)
2 (3.5%) 526 CAC ! GAC (His) ! (Asp); 533 CTG ! CGT (Leu) ! (Arg)
1 (1.7%) 531 TCG ! TTG (Ser) ! (Leu); 533 CTG ! GGC (Leu) ! (Gly)
1 (1.7%) 526 CAC ! CAG (His) ! (Gln); 533 CTG ! CCG (Leu) ! (Pro)
1 (1.7%) 526 CAC ! CGC (His) ! (Arg); 529 CGA ! CAA (Arg) ! (Gln); 533 CTG ! CGT (Leu) ! (Arg)
1 (1.7%) 531 TCG ! ATT (Ser) ! (Ile); 533 CTG ! CCG (Leu) ! (Pro)
1 (1.7%) 525 ACC ! ATC (Thr) ! (Ile); 531 TCG ! TTG (Ser) ! (Leu)
1 (1.7%) 526 CAC ! TGC (His) ! (Cys); 533 CTG ! CGC (Leu) ! (Arg)
1 (1.7%) G deletion position 15; 533 CTG ! CCG (Leu) ! (Pro)
1 (1.7%) 517 CAG ! CCA (Gln) ! (Pro); 531 TCG ! TTG (Ser) ! (Leu); 533 CTG ! CGG (Leu) ! (Arg)
1 (1.7%) 512 AGC ! CTC (Ser) ! (Leu); 513 CAA ! CCA (Gln) ! (Pro);
524 TTG ! CTC (Leu) ! (Leu); 529 CGA ! CGC (Arg) ! (Arg); 533 CTG ! CGT (Leu) ! (Arg)
1 (1.7%) 516 GAC ! CTC (Asp) ! (Leu); 517 CAG ! CAA (Gln) ! (Gln); 533 CTG ! CGG (Leu) ! (Arg)
1 (1.7%) 531 TCG ! TTG (Ser) ! (Leu); 533 CTG ! GCG (Leu) ! (Ala)
1 (1.7%) 516 GAC ! GTC (Asp) ! (Val)
1 (1.7%) 526 CAC ! GCA (His) ! (Asp); 532 GCG ! GGC (Ala) ! (Gly); 533 CTG ! CGG (Leu) ! (Arg)
1 (1.7%) 511 CTG ! CCG (Leu) ! (Pro); 533 CTG ! CGT (Leu) ! (Arg)
1 (1.7%) 517 CAG ! AGA (Gln) ! (Arg); 531 TCG ! TTG (Ser) ! (Leu)
1 (1.7%) 531 TCG ! TTG (Ser) ! (Leu)
1 (1.7%) 531 TCG ! TTG (Ser) ! (Leu); 532 GCG ! CGC (Ala) ! (Arg); 533 CTG ! TGG (Leu) ! (Trp)
1 (1.7%) 513 CAA ! CAG (Gln) ! (Gln); 533 CTG ! CCG (Leu) ! (Pro)
1 (1.7%) 526 CAC ! GAC (His) ! (Asp)
1 (1.7%) 531 TCG ! TGC (Ser) ! (Cys)
1 (1.7%) 512 AGC ! ACC (Ser) ! (Thr); 531 TCG ! TTG (Ser) ! (Leu)
1 (1.7%) 533 CTG ! CGT (Leu) ! (Arg)
1 (1.7%) 512 AGC ! TCG (Ser) ! (Ser); 513 CAA ! CCA (Gln) ! (Pro); 533 CTG ! CCG (Leu) ! (Pro)
Table 2 – Mutations identified within loci associated with resistance to Isoniazid.
Codon 315 katG mutations
(Amino acid change); (Nb, %)
InhA promoter
mutations; (Nb, %)
ahpC-oxyR
intergenic; (Nb, %)
Reference strain ATCC 25177 AGC () – –
M. tuberculosis strains (n = 66) AGC ! ACC (Ser ! Thr); (26, 39.3%) 15 C-T; (14, 21.2%) 46 G-A; (4, 6.0%)
AGC ! ATC (Ser ! Ile); (1, 1.5%) 6 G-A; (1, 1.5%)
AGC ! AAC (Ser ! Asn); (1, 1.5%) 12 G-T; (1, 1.5%)
Sensitivity 42.4% 21.2% 9.0%
Total sensitivity 72.6%
Table 1 – Primer sequences for PCR and pyrosequencing.
Genes F (50–3 0) R-biotinylated (50–30) Sequencing primer (5 0–3 0)
katG TCGGCGATGAGCGTT-ACAGC CCCGCAGCGAGAGGTC-AGTGG CATACGACCTCGATGC
inhA TTACGCTCGTGGACA-TACCG CTGAACGGGATACGAA-TGG GCCCGG
ahpC-oxyR CGGCACTGCTGAACC-ACTG CCTCATCATCAAAGCG-GACAATG CATTTGGTTGCGACAT
rpoB RDR GGAGCGGATGACCA-CCCAGGAC AGCGAGCCGATCAGAC-CGATGTT 1-GCGATCAAGGAGTTCTTC
2-CCAGAACAACCCGCT
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were accompanied by non-silent mutations. Codon changes
occurred primarily at codons 531 (37/97: 38%), 533 (28/97:
29%) and 526 (9/97: 9%). The mutation S531 L (TCG/TTG)was by far the most frequent (35 patients: 35/56: 63%).
Fig. 1 shows a representative DNA sequence analysis of 81-
bp RRDR core region of rpoB gene of RIF-resistant isolates
of MTB.
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Fig. 1 – Representative DNA sequence analysis of 81-bp core region (RRDR) of rpoB gene of Rifampicin resistance isolates of
M. tuberculosis.
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Pyrosequencing performs real-time sequencing of short DNA
segments at a speed averaging 1 min per nucleotide. In this
study, the pyrosequencing method was evaluated for MTB
resistance detection; 66 clinical isolates resistant to INH
were subjected to katG, inhA promoter region and ahpC-
oxyR intergenic region mutations detection, and 56 strains
resistant to RIF were subjected to rpoB region (507–533)
mutations detection. This study showed that the pyrose-
quencing applied to katG, inhA promoter and ahpC-oxyR
intergenic region was able to detect a relatively large propor-
tion of INH-resistant strains (72.6%). It is quite possible the
presence of other mechanisms of resistance were mediated
by the changes in other chromosome loci, e.g., kasA, dfrA
and ndh [4]. The use of a single codon 315 katG mutation
for INH resistance is not accurate in this country since it will
lead to a sensitivity of only 42.4%. The prevalence of muta-
tions in katG varies strongly among different regions of the
world. The mutation rate was 98% in Russia [11], 66.7% in
Finland [12], 60% in South Africa [13] and China [14], 46%
in Switzerland [15] and 37% in Italy [16]. To improve the sen-
sitivity of pyrosequencing for INH detection, 2 loci (inhA pro-
moter and ahpC-oxyR intergenic region) were added. In a
study [17] conducted by Huang et al., 18 of 28 MDR-TB iso-
lates possessed ahpC mutations alone or in addition to
katG mutations outside of codon 315. Detection of INH resis-
tance from these isolates was missed by the MTBDRplus
assay; this demonstrated the significance of adding the
ahpC locus for detecting INH resistance. The present study
found a rather small increase (9.0%) in sensitivity con-
tributed by ahpC. However, any increase in the detection of
INH resistance reduces ineffective INH treatment and pro-
phylaxis and is welcomed by clinicians. A recent study in
the United States of America showed a sensitivity of 88.6%
by using the 3 loci [18].RIF is a powerful drug used for treating TB. The accuracy of
molecular testing for RIF resistance is critical, since it may
influence early clinical decisions. The frequencies of muta-
tions detected (100%) for rpoB in RIF-resistant isolates by the
pyrosequencing assay are consistent with other reports in
the literature and demonstrates the importance of the RRDR
hotspot region in the resistance of clinical TB isolates.
Several studies have indicated that this region is responsible
for 90–95% of RIF-resistant cases [19]. Notably, the vast major-
ity of patients (95%) had mutations in codons 531 and/or 533.
This could greatly reduce the expense and complexity of
future early detection efforts in the local patient pool. The
present study also emphasizes the frequency of codon
changes at position 533. In clear contrast to previous reports
[20,21], the majority of isolates in this study exhibited more
than 1 codon change (2–5). Many codon changes involved
more than one base pair change. A significant portion
appeared to involve a two-base pair inversion, while others
were likely to involve multiple base pair substitutions through
point mutations. The high GC/AT ratio may contribute mech-
anistically to the mutability of this hot spot region.
The main advantage of this assay is its rapidity compared
with that of conventional testing. This characteristic, coupled
with the excellent specificity for detection of resistance to the
two most important anti-tuberculosis medications in the
majority of cases, makes this assay potentially useful by
allowing appropriate treatment several days or weeks sooner
than would be possible with conventional testing.
Pyrosequencing, however, still cannot supplant conventional
phenotypic methods of resistance testing. Where there are
multiple genetic bases for resistance or where all the mecha-
nisms of resistance have not been identified, genotypic meth-
ods have limitations. For instance, this assay looks for
resistance only in the katG, inhA and ahpC-oxyR for INH resis-
tance. For this drug, there remain other genetic mechanisms
for resistance outside the three tested loci. Where the genetic
232 I n t e r n a t i o n a l J o u r n a l o f M y c o b a c t e r i o l o g y 4 ( 2 0 1 5 ) 2 2 8 –2 3 2basis for resistance has been identified, it should be possible
to develop genotypic assays to detect resistance. However,
practical considerations limit the numbers of assays that
can be run for each sample, and costs and complexities of
testing additional sites have to be weighed against the incre-
mental benefits of such testing in clinical practice.
Conclusion
Pyrosequencing is a rapid and accurate method for detecting
MTB resistance to RIF and INH. The accuracy of sequencing by
pyrosequencing is comparable to that of Sanger sequencing,
and the availability of sequence information enables users
to study the association of drug minimum inhibitory concen-
trations (MICs) with each mutation. Once sufficient data asso-
ciating specific mutations with MIC distributions have been
accumulated, pyrosequencing may become a useful tool for
predicting the level of drug resistance. Such information
may help guide treatment decisions before the availability
of phenotypic DST results. Based on the outcome of this
study, a larger field trial of this assay is under way in Lebanon.
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